Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDT NASDAQ:FLGT NASDAQ:LFST NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health$10.97-1.3%$13.88$10.96▼$20.72$1.57BN/A365,283 shs130,354 shsFLGTFulgent Genetics$17.74-0.2%$20.12$14.57▼$25.11$539.38M1.03284,925 shs46,805 shsLFSTLifeStance Health Group$4.19-0.8%$5.29$4.19▼$8.61$1.63B1.161.68 million shs406,328 shsVCYTVeracyte$23.30-0.9%$27.15$19.73▼$47.32$1.82B2.07918,090 shs144,813 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health0.00%-21.42%-14.40%-3.96%-35.55%FLGTFulgent Genetics0.00%-7.73%-8.96%-0.78%-18.52%LFSTLifeStance Health Group0.00%-6.43%-12.63%-31.49%-23.27%VCYTVeracyte0.00%-13.18%-10.91%-23.17%+1.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDTArdent Health3.3882 of 5 stars3.50.00.00.02.50.03.1FLGTFulgent Genetics3.7884 of 5 stars3.31.00.04.11.13.30.6LFSTLifeStance Health Group3.086 of 5 stars3.43.00.00.03.02.50.6VCYTVeracyte3.7675 of 5 stars3.41.00.04.33.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health 2.92Moderate Buy$20.3085.05% UpsideFLGTFulgent Genetics 2.50Moderate Buy$24.0035.26% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.50103.11% UpsideVCYTVeracyte 2.70Moderate Buy$40.9075.57% UpsideCurrent Analyst Ratings BreakdownLatest FLGT, LFST, VCYT, and ARDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025ARDTArdent HealthBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$15.50 ➝ $14.605/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/20/2025ARDTArdent HealthStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.005/15/2025ARDTArdent HealthRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.005/9/2025ARDTArdent HealthGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health$5.97B0.26$2.50 per share4.38$10.66 per share1.03FLGTFulgent Genetics$292.45M1.85N/AN/A$36.92 per share0.48LFSTLifeStance Health Group$1.25B1.30$0.04 per share106.42$3.78 per share1.11VCYTVeracyte$445.76M4.09$1.03 per share22.67$15.17 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health$210.34M$1.636.735.604.663.73%16.07%4.69%8/13/2025 (Estimated)FLGTFulgent Genetics-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)LFSTLifeStance Health Group-$57.44M-$0.10N/AN/AN/A-2.78%-2.47%-1.69%8/14/2025 (Estimated)VCYTVeracyte$24.14M$0.4156.7832.35N/A7.13%6.14%5.60%8/6/2025 (Estimated)Latest FLGT, LFST, VCYT, and ARDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LFSTLifeStance Health Group-$0.03N/AN/AN/AN/AN/A8/13/2025Q2 2025ARDTArdent Health$0.51N/AN/AN/AN/AN/A8/6/2025Q2 2025VCYTVeracyte$0.31N/AN/AN/A$120.90 millionN/A8/1/2025Q2 2025FLGTFulgent Genetics-$0.23N/AN/AN/A$76.21 millionN/A5/6/2025Q1 2025ARDTArdent Health$0.21$0.29+$0.08$0.29$1.50 billion$1.50 billion5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent HealthN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health0.702.121.98FLGTFulgent GeneticsN/A6.326.32LFSTLifeStance Health Group0.191.471.47VCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent HealthN/AFLGTFulgent Genetics48.06%LFSTLifeStance Health Group85.50%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipARDTArdent Health1.70%FLGTFulgent Genetics31.76%LFSTLifeStance Health Group6.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health24,900143.04 million140.61 millionOptionableFLGTFulgent Genetics1,31330.44 million20.36 millionOptionableLFSTLifeStance Health Group10,218388.88 million363.21 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionableFLGT, LFST, VCYT, and ARDT HeadlinesRecent News About These CompaniesBrokerages Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $40.90July 21 at 2:15 AM | americanbankingnews.comJennison Associates LLC Buys 166,605 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 20 at 5:45 AM | marketbeat.comVeracyte (NASDAQ:VCYT) Trading Down 5.9% - Here's WhyJuly 19 at 4:36 PM | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Veracyte, Inc. (NASDAQ:VCYT)July 19 at 11:08 AM | marketbeat.comVeracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18July 18 at 1:43 PM | gurufocus.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 18 at 2:41 AM | marketbeat.comVeracyte to Release Second Quarter 2025 Financial Results on August 6, 2025July 17, 2025 | businesswire.comSegall Bryant & Hamill LLC Has $13.90 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)July 17, 2025 | marketbeat.comShould You Continue to Hold Veracyte Stock in Your Portfolio Now?July 16, 2025 | zacks.comNew York State Common Retirement Fund Sells 118,642 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 16, 2025 | marketbeat.comRice Hall James & Associates LLC Acquires 19,843 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 15, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of TexasJuly 14, 2025 | marketbeat.comVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - MorningstarJuly 10, 2025 | morningstar.comMVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025July 9, 2025 | tmcnet.comWealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)July 6, 2025 | marketbeat.comVeracyte, Inc. (VCYT) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 1, 2025 | marketbeat.comWall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to HoldJune 28, 2025 | marketbeat.comAMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)June 26, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from AnalystsJune 23, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGT, LFST, VCYT, and ARDT Company DescriptionsArdent Health NYSE:ARDT$10.97 -0.14 (-1.26%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Fulgent Genetics NASDAQ:FLGT$17.74 -0.04 (-0.21%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.LifeStance Health Group NASDAQ:LFST$4.18 -0.04 (-0.83%) As of 11:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Veracyte NASDAQ:VCYT$23.30 -0.22 (-0.91%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
